Characterizing the human intestinal chondroitin sulfate glycosaminoglycan sulfation signature in inflammatory bowel disease.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
23 05 2024
23 05 2024
Historique:
received:
21
12
2023
accepted:
29
04
2024
medline:
24
5
2024
pubmed:
24
5
2024
entrez:
23
5
2024
Statut:
epublish
Résumé
The intestinal extracellular matrix (ECM) helps maintain appropriate tissue barrier function and regulate host-microbial interactions. Chondroitin sulfate- and dermatan sulfate-glycosaminoglycans (CS/DS-GAGs) are integral components of the intestinal ECM, and alterations in CS/DS-GAGs have been shown to significantly influence biological functions. Although pathologic ECM remodeling is implicated in inflammatory bowel disease (IBD), it is unknown whether changes in the intestinal CS/DS-GAG composition are also linked to IBD in humans. Our aim was to characterize changes in the intestinal ECM CS/DS-GAG composition in intestinal biopsy samples from patients with IBD using mass spectrometry. We characterized intestinal CS/DS-GAGs in 69 pediatric and young adult patients (n = 13 control, n = 32 active IBD, n = 24 IBD in remission) and 6 adult patients. Here, we report that patients with active IBD exhibit a significant decrease in the relative abundance of CS/DS isomers associated with matrix stability (CS-A and DS) compared to controls, while isomers implicated in matrix instability and inflammation (CS-C and CS-E) were significantly increased. This imbalance of intestinal CS/DS isomers was restored among patients in clinical remission. Moreover, the abundance of pro-stabilizing CS/DS isomers negatively correlated with clinical disease activity scores, whereas both pro-inflammatory CS-C and CS-E content positively correlated with disease activity scores. Thus, pediatric patients with active IBD exhibited increased pro-inflammatory and decreased pro-stabilizing CS/DS isomer composition, and future studies are needed to determine whether changes in the CS/DS-GAG composition play a pathogenic role in IBD.
Identifiants
pubmed: 38782973
doi: 10.1038/s41598-024-60959-x
pii: 10.1038/s41598-024-60959-x
doi:
Substances chimiques
Chondroitin Sulfates
9007-28-7
Glycosaminoglycans
0
chondroitin sulfate glycosaminoglycan
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
11839Subventions
Organisme : NIDDK NIH HHS
ID : DK131695
Pays : United States
Organisme : NIDDK NIH HHS
ID : DK089056
Pays : United States
Organisme : NIDDK NIH HHS
ID : DK101997
Pays : United States
Organisme : NIDDK NIH HHS
ID : DK017047
Pays : United States
Organisme : NIDDK NIH HHS
ID : DK114474
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM127579
Pays : United States
Organisme : National Institute of Allergy and Infectious Diseases
ID : AI171150
Organisme : NIA NIH HHS
ID : R21 AG074152
Pays : United States
Organisme : U.S. Department of Defense
ID : W81XWH2110635
Organisme : Office of Research Central, University of Washington
ID : A139339
Informations de copyright
© 2024. The Author(s).
Références
Atlab, S. et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 5, 17–30 (2019).
Chudy-Onwugaje, K. O., Christian, K. E., Farraye, F. A. & Cross, R. K. A state-of-the-art review of new and emerging therapies for the treatment of IBD. Inflamm. Bowel Dis. 25, 820–830 (2018).
pmcid: 6468492
doi: 10.1093/ibd/izy327
Villablanca, E. J., Selin, K. & Hedin, C. R. H. Mechanisms of mucosal healing: Treating inflammatory bowel disease without immunosuppression?. Nat. Rev. Gastroenterol. https://doi.org/10.1038/s41575-022-00604-y (2022).
doi: 10.1038/s41575-022-00604-y
Cai, Z., Wang, S. & Li, J. Treatment of inflammatory bowel disease: A comprehensive review. Front. Med. 8, 765474 (2021).
doi: 10.3389/fmed.2021.765474
Lichtenstein, G. R. et al. ACG clinical guideline: Management of Crohn’s disease in adults. Am. J. Gastroenterol. 113, 481–517 (2018).
pubmed: 29610508
doi: 10.1038/ajg.2018.27
Worley, G. et al. Colectomy rates for ulcerative colitis in England 2003–2016. Aliment. Pharm. Ther. 53, 484–498 (2021).
doi: 10.1111/apt.16202
Yang, E. et al. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn’s disease. Aliment. Pharm. Ther. 51, 1031–1038 (2020).
doi: 10.1111/apt.15719
de Chambrun, G. P., Peyrin-Biroulet, L., Lémann, M. & Colombel, J.-F. Clinical implications of mucosal healing for the management of IBD. Nat. Rev. Gastroenterol. 7, 15–29 (2010).
doi: 10.1038/nrgastro.2009.203
Ungaro, R. C. et al. Deep remission at 1 year prevents progression of early Crohn’s disease. Gastroenterology 159, 139–147 (2020).
pubmed: 32224129
doi: 10.1053/j.gastro.2020.03.039
Carvalho, P. B. & Cotter, J. Mucosal healing in ulcerative colitis: A comprehensive review. Drugs 77, 159–173 (2017).
doi: 10.1007/s40265-016-0676-y
Neurath, M. F. New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal. Immunol. 7, 6–19 (2014).
pubmed: 24084775
doi: 10.1038/mi.2013.73
Guan, Q. A comprehensive review and update on the pathogenesis of inflammatory bowel disease. J. Immunol. Res. 2019, 7247238 (2019).
pubmed: 31886308
pmcid: 6914932
doi: 10.1155/2019/7247238
Zhang, Y.-Z. & Li, Y.-Y. Inflammatory bowel disease: Pathogenesis. World J. Gastroenterol. 20, 91–99 (2014).
pubmed: 24415861
pmcid: 3886036
doi: 10.3748/wjg.v20.i1.91
Xavier, R. J. & Podolsky, D. K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448, 427–434 (2007).
pubmed: 17653185
doi: 10.1038/nature06005
Chang, J. et al. Impaired intestinal permeability contributes to ongoing bowel symptoms in patients with inflammatory bowel disease and mucosal healing. Gastroenterology 153, 723-731.e1 (2017).
pubmed: 28601482
doi: 10.1053/j.gastro.2017.05.056
Kang, Y., Park, H., Choe, B.-H. & Kang, B. The role and function of mucins and its relationship to inflammatory bowel disease. Front. Med. 9, 848344 (2022).
doi: 10.3389/fmed.2022.848344
d’Aldebert, E. et al. Characterization of human colon organoids from inflammatory bowel disease patients. Front. Cell Dev. Biol. 8, 363 (2020).
pubmed: 32582690
pmcid: 7287042
doi: 10.3389/fcell.2020.00363
Golusda, L., Kühl, A. A., Siegmund, B. & Paclik, D. Extracellular matrix components as diagnostic tools in inflammatory bowel disease. Biology 10, 1024 (2021).
pubmed: 34681123
pmcid: 8533508
doi: 10.3390/biology10101024
Petrey, A. C. & de la Motte, C. A. The extracellular matrix in IBD. Curr. Opin. Gastroenterol. 33, 234–238 (2017).
pubmed: 28562487
pmcid: 5562400
doi: 10.1097/MOG.0000000000000368
Derkacz, A., Olczyk, P., Olczyk, K. & Komosinska-Vassev, K. The role of extracellular matrix components in inflammatory bowel diseases. J. Clin. Med. 10, 1122 (2021).
pubmed: 33800267
pmcid: 7962650
doi: 10.3390/jcm10051122
Pompili, S., Latella, G., Gaudio, E., Sferra, R. & Vetuschi, A. The charming world of the extracellular matrix: A dynamic and protective network of the intestinal wall. Front. Med. 8, 610189 (2021).
doi: 10.3389/fmed.2021.610189
Derkacz, A., Olczyk, P., Jura-Półtorak, A., Olczyk, K. & Komosinska-Vassev, K. The diagnostic usefulness of circulating profile of extracellular matrix components: Sulfated glycosaminoglycans (sGAG), hyaluronan (HA) and extracellular part of syndecan-1 (sCD138) in patients with Crohn’s disease and ulcerative colitis. J. Clin. Med. 10, 1722 (2021).
pubmed: 33923501
pmcid: 8073401
doi: 10.3390/jcm10081722
Kechagia, J. Z., Ivaska, J. & Roca-Cusachs, P. Integrins as biomechanical sensors of the microenvironment. Nat. Rev. Mol. Cell Biol. 20, 457–473 (2019).
pubmed: 31182865
doi: 10.1038/s41580-019-0134-2
Asano, K., Yoshimura, S. & Nakane, A. Alteration of intestinal microbiota in mice orally administered with salmon cartilage proteoglycan, a prophylactic agent. PLoS ONE 8, e75008 (2013).
pubmed: 24040376
pmcid: 3767651
doi: 10.1371/journal.pone.0075008
Sashinami, H. et al. Salmon proteoglycan suppresses progression of mouse experimental autoimmune encephalomyelitis via regulation of Th17 and Foxp3+ regulatory T cells. Life Sci. 91, 1263–1269 (2012).
pubmed: 23069584
doi: 10.1016/j.lfs.2012.09.022
Kudo, K., Kobayashi, T., Kasai, K., Nozaka, H. & Nakamura, T. Chondroitin sulfate is not digested at all in the mouse small intestine but may suppress interleukin 6 expression induced by tumor necrosis factor-α. Biochem. Biophys. Res. Commun. 642, 185–191 (2023).
pubmed: 36586186
doi: 10.1016/j.bbrc.2022.12.051
Mortensen, J. H. et al. The intestinal tissue homeostasis: The role of extracellular matrix remodeling in inflammatory bowel disease. Expert. Rev. Gastroenterol. 13, 1–17 (2019).
Mikami, T. & Kitagawa, H. Chondroitin sulfate glycosaminoglycans function as extra/pericellular ligands for cell surface receptors. J. Biochem. 173, 329–332 (2023).
pubmed: 36611203
doi: 10.1093/jb/mvac110
Miyata, S. & Kitagawa, H. Chondroitin 6-sulfation regulates perineuronal net formation by controlling the stability of aggrecan. Neural Plast. 2016, 1–13 (2016).
doi: 10.1155/2016/1305801
Ryu, Y., Iwashita, M., Lee, W., Uchimura, K. & Kosodo, Y. A shift in tissue stiffness during hippocampal maturation correlates to the pattern of neurogenesis and composition of the extracellular matrix. Front. Aging Neurosci. 13, 709620 (2021).
pubmed: 34393762
pmcid: 8361493
doi: 10.3389/fnagi.2021.709620
Miyata, S., Komatsu, Y., Yoshimura, Y., Taya, C. & Kitagawa, H. Persistent cortical plasticity by upregulation of chondroitin 6-sulfation. Nat. Neurosci. 15, 414–422 (2012).
pubmed: 22246436
doi: 10.1038/nn.3023
Mizumoto, S. & Yamada, S. The specific role of dermatan sulfate as an instructive glycosaminoglycan in tissue development. Int. J. Mol. Sci. 23, 7485 (2022).
pubmed: 35806490
pmcid: 9267682
doi: 10.3390/ijms23137485
Rizzo-Valente, V. S. et al. Effects of dermatan sulfate from marine invertebrate styela plicata in the wound healing pathway: A natural resource applied to regenerative therapy. Mar. Drugs 20, 676 (2022).
pubmed: 36354999
pmcid: 9693086
doi: 10.3390/md20110676
Trowbridge, J. M. & Gallo, R. L. Dermatan sulfate: New functions from an old glycosaminoglycan. Glycobiology 12, 117R-125R (2002).
pubmed: 12213784
doi: 10.1093/glycob/cwf066
Logsdon, A. F. et al. Decoding perineuronal net glycan sulfation patterns in the Alzheimer’s disease brain. Alzheimer’s Dement. https://doi.org/10.1002/alz.12451 (2021).
doi: 10.1002/alz.12451
Suzuki, K. et al. Pivotal role of carbohydrate sulfotransferase 15 in fibrosis and mucosal healing in mouse colitis. PLoS ONE 11, e0158967 (2016).
pubmed: 27410685
pmcid: 4943596
doi: 10.1371/journal.pone.0158967
Ohtake, S. et al. Expression of sulfotransferases involved in the biosynthesis of chondroitin sulfate E in the bone marrow derived mast cells. Biochim. Biophys. Acta Gen. Subj. 1780, 687–695 (2008).
doi: 10.1016/j.bbagen.2008.01.004
Habuchi, O., Moroi, R. & Ohtake, S. Enzymatic synthesis of chondroitin sulfate E by N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase purified from squid cartilage. Anal. Biochem. 310, 129–136 (2002).
pubmed: 12423630
doi: 10.1016/S0003-2697(02)00277-4
Gilbert, R. J. et al. CS-4,6 is differentially upregulated in glial scar and is a potent inhibitor of neurite extension. Mol. Cell. Neurosci. 29, 545–558 (2005).
pubmed: 15936953
doi: 10.1016/j.mcn.2005.04.006
Alonge, K. M. et al. Changes in brain matrix glycan sulfation associate with reactive gliosis and motor coordination in mice with head trauma. Front. Behav. Neurosci. 15, 745288 (2021).
pubmed: 34776892
pmcid: 8581466
doi: 10.3389/fnbeh.2021.745288
Shida, M., Mikami, T., Tamura, J. & Kitagawa, H. Chondroitin sulfate-D promotes neurite outgrowth by acting as an extracellular ligand for neuronal integrin αVβ3. Biochim. Biophys. Acta Gen. Subj. 1863, 1319–1331 (2019).
pubmed: 31181256
doi: 10.1016/j.bbagen.2019.06.004
Syková, E. & Nicholson, C. Diffusion in brain extracellular space. Physiol. Rev. 88, 1277–1340 (2008).
pubmed: 18923183
doi: 10.1152/physrev.00027.2007
Reine, T. M. et al. Reduced sulfation of chondroitin sulfate but not heparan sulfate in kidneys of diabetic db/db mice. J. Histochem. Cytochem. 61, 606–616 (2013).
pubmed: 23757342
pmcid: 3724391
doi: 10.1369/0022155413494392
Scarlett, J. M., Hu, S. J. & Alonge, K. M. The, “loss” of perineuronal nets in Alzheimer’s disease: missing or hiding in plain sight?. Front. Integr. Neurosci. 16, 896400 (2022).
pubmed: 35694184
pmcid: 9174696
doi: 10.3389/fnint.2022.896400
Alonge, K. M. et al. Hypothalamic perineuronal net assembly is required for sustained diabetes remission induced by fibroblast growth factor 1 in rats. Nat. Metab. 2, 1025–1033 (2020).
pubmed: 32895577
pmcid: 7572652
doi: 10.1038/s42255-020-00275-6
Logsdon, A. F. et al. Perineuronal net deglycosylation associates with tauopathy-induced gliosis and neurodegeneration. J. Neurochem. https://doi.org/10.1111/jnc.16067 (2024).
doi: 10.1111/jnc.16067
pubmed: 38317026
Han, C. Y. et al. Adipocyte-derived versican and macrophage-derived biglycan control adipose tissue inflammation in obesity. Cell Rep. 31, 107818 (2020).
pubmed: 32610121
pmcid: 7384517
doi: 10.1016/j.celrep.2020.107818
Odenwald, M. A. & Turner, J. R. The intestinal epithelial barrier: A therapeutic target?. Nat. Rev. Gastroenterol. Hepatol. 14, 9–21 (2017).
pubmed: 27848962
doi: 10.1038/nrgastro.2016.169
Friedrich, M., Pohin, M. & Powrie, F. Cytokine networks in the pathophysiology of inflammatory bowel disease. Immunity 50, 992–1006 (2019).
pubmed: 30995511
doi: 10.1016/j.immuni.2019.03.017
Kudelka, M. R., Stowell, S. R., Cummings, R. D. & Neish, A. S. Intestinal epithelial glycosylation in homeostasis and gut microbiota interactions in IBD. Nat. Rev. Gastroenterol. 17, 597–617 (2020).
doi: 10.1038/s41575-020-0331-7
Bergstrom, K. et al. Defective intestinal mucin-type O-glycosylation causes spontaneous colitis-associated cancer in mice. Gastroenterology 151, 152-164.e11 (2016).
pubmed: 27059389
doi: 10.1053/j.gastro.2016.03.039
Rausch, P. et al. Colonic mucosa-associated microbiota is influenced by an interaction of Crohn disease and FUT2 (Secretor) genotype. Proc. Natl. Acad. Sci. 108, 19030–19035 (2011).
pubmed: 22068912
pmcid: 3223430
doi: 10.1073/pnas.1106408108
Fu, J. et al. Loss of intestinal core 1–derived O-glycans causes spontaneous colitis in mice. J. Clin. Invest. 121, 1657–1666 (2011).
pubmed: 21383503
pmcid: 3069788
doi: 10.1172/JCI45538
Alonge, K. M. et al. Quantitative analysis of chondroitin sulfate disaccharides from human and rodent fixed brain tissue by electrospray ionization-tandem mass spectrometry. Glycobiology 29, 847–860 (2019).
pubmed: 31361007
pmcid: 6861844
doi: 10.1093/glycob/cwz060
Härtig, W., Meinicke, A., Michalski, D., Schob, S. & Jäger, C. Update on perineuronal net staining with Wisteria floribunda agglutinin (WFA). Front. Integr. Neurosci. 16, 851988 (2022).
pubmed: 35431825
pmcid: 9011100
doi: 10.3389/fnint.2022.851988
Hilbig, H., Bidmon, H.-J., Blohm, U. & Zilles, K. Wisteria floribunda agglutinin labeling patterns in the human cortex: A tool for revealing areal borders and subdivisions in parallel with immunocytochemistry. Anat. Embryol. 203, 45–52 (2001).
doi: 10.1007/s004290000135
Taleb, V. et al. Structural and mechanistic insights into the cleavage of clustered O-glycan patches-containing glycoproteins by mucinases of the human gut. Nat. Commun. 13, 4324 (2022).
pubmed: 35882872
pmcid: 9325726
doi: 10.1038/s41467-022-32021-9
Prabhakar, V., Capila, I., Soundararajan, V., Raman, R. & Sasisekharan, R. Recombinant expression, purification, and biochemical characterization of chondroitinase ABC II from Proteus vulgaris*. J. Biol. Chem. 284, 974–982 (2009).
pubmed: 18849565
pmcid: 2613618
doi: 10.1074/jbc.M806630200
Hamai, A. et al. Two distinct chondroitin sulfate ABC lyases an endoeliminase yielding tertasaccharides and an exoeliminase preferentially acting on oligosaccharides. J. Biol. Chem. 272, 9123–9130 (1997).
pubmed: 9083041
doi: 10.1074/jbc.272.14.9123
Yi, J. et al. Alterations in sulfated chondroitin glycosaminoglycans following controlled cortical impact injury in mice. J. Comp. Neurol. 520, 3295–3313 (2012).
pubmed: 22628090
pmcid: 3806093
doi: 10.1002/cne.23156
Darwich, A. S., Aslam, U., Ashcroft, D. M. & Rostami-Hodjegan, A. meta-analysis of the turnover of intestinal epithelia in preclinical animal species and humans. Drug Metab. Dispos. 42, 2016–2022 (2014).
pubmed: 25233858
doi: 10.1124/dmd.114.058404
van der Flier, L. G. & Clevers, H. Stem cells, self-renewal, and differentiation in the intestinal epithelium. Annu. Rev. Physiol. 71, 241–260 (2009).
pubmed: 18808327
doi: 10.1146/annurev.physiol.010908.163145
Hussein, R. K., Mencio, C. P., Katagiri, Y., Brake, A. M. & Geller, H. M. Role of chondroitin sulfation following spinal cord injury. Front. Cell Neurosci. 14, 208 (2020).
pubmed: 32848612
pmcid: 7419623
doi: 10.3389/fncel.2020.00208
Hong, T.-T., White, A. J. & Lucchesi, B. R. Dermatan disulfate (Intimatan) prevents complement-mediated myocardial injury in the human-plasma-perfused rabbit heart. Int. Immunopharmacol. 5, 381–391 (2005).
pubmed: 15652767
doi: 10.1016/j.intimp.2004.10.013
Dehghani, T. et al. Selectin-targeting glycosaminoglycan-peptide conjugate limits neutrophil-mediated cardiac reperfusion injury. Cardiovasc. Res. 118, 267–281 (2020).
pmcid: 8932156
doi: 10.1093/cvr/cvaa312
Murch, S. H. et al. Disruption of sulphated glycosaminoglycans in intestinal inflammation. Lancet 341, 711–714 (1993).
pubmed: 8095623
doi: 10.1016/0140-6736(93)90485-Y
Habuchi, O. Functions of chondroitin/dermatan sulfate containing GalNAc4,6-disulfate. Glycobiology 32, 664–678 (2022).
pubmed: 35552694
doi: 10.1093/glycob/cwac030
Testa, D., Prochiantz, A. & Nardo, A. A. D. Perineuronal nets in brain physiology and disease. Semin. Cell Dev. Biol. 89, 125–135 (2018).
pubmed: 30273653
doi: 10.1016/j.semcdb.2018.09.011
Morawski, M. et al. Involvement of perineuronal and perisynaptic extracellular matrix in Alzheimer’s disease neuropathology. Brain Pathol. 22, 547–561 (2012).
pubmed: 22126211
pmcid: 3639011
doi: 10.1111/j.1750-3639.2011.00557.x
Pantazopoulos, H. & Berretta, S. In sickness and in health: Perineuronal nets and synaptic plasticity in psychiatric disorders. Neural Plast. 2016, 1–23 (2016).
doi: 10.1155/2016/9847696
Allaire, J. M. et al. The intestinal epithelium: Central coordinator of mucosal immunity. Trends Immunol. 39, 677–696 (2018).
pubmed: 29716793
doi: 10.1016/j.it.2018.04.002
Wallace, K. L., Zheng, L.-B., Kanazawa, Y. & Shih, D. Q. Immunopathology of inflammatory bowel disease. World J. Gastroenterol. 20, 6–21 (2014).
pubmed: 24415853
pmcid: 3886033
doi: 10.3748/wjg.v20.i1.6
Mohan, H. et al. Extracellular matrix in multiple sclerosis lesions: Fibrillar collagens, biglycan and decorin are upregulated and associated with infiltrating immune cells. Brain Pathol. 20, 966–975 (2010).
pubmed: 20456365
pmcid: 8094740
doi: 10.1111/j.1750-3639.2010.00399.x
Chalkidi, N., Paraskeva, C. & Koliaraki, V. Fibroblasts in intestinal homeostasis, damage, and repair. Front. Immunol. 13, 924866 (2022).
pubmed: 36032088
pmcid: 9399414
doi: 10.3389/fimmu.2022.924866
Hori, Y. et al. Effects of chondroitin sulfate on colitis induced by dextran sulfate sodium in rats. Jpn. J. Pharmacol. 85, 155–160 (2001).
pubmed: 11286397
doi: 10.1254/jjp.85.155
Severs, M. et al. Sex-related differences in patients with inflammatory bowel disease: Results of two prospective cohort studies. Inflamm. Bowel Dis. 24, 1298–1306 (2018).
pubmed: 29688413
doi: 10.1093/ibd/izy004
Turner, D. et al. Appraisal of the pediatric ulcerative colitis activity index (PUCAI). Inflamm. Bowel Dis. 15, 1218–1223 (2009).
pubmed: 19161178
doi: 10.1002/ibd.20867
Hyams, J. et al. Evaluation of the pediatric Crohn disease activity index: A prospective multicenter experience. J. Pediatr. Gastroenterol. Nutr. 41, 416–421 (2005).
pubmed: 16205508
doi: 10.1097/01.mpg.0000183350.46795.42